JANX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Janux Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 15.17 USD
-1.0% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 5.6% above the Trend Line and sits at 13.1% of its 52-week range. The latest completed week returned -1.0%, after a -2.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 38/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 31 out of 100
Latest Close 15.17 USD 31 Jul 2026
1W Return -1.0% latest completed week
4W Return -2.4% short-term follow-through
12W Return 7.0% quarterly tape
Trend Breadth 15.4% 8 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • 5 accumulation markers appear in the recent smart-money tape.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 43.46% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.0% Latest completed week; four-week move -2.4%. Indicator stack 26/68 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.46% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 38/100 conviction; expected move 15.2%. News sentiment 51/100 57 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 5.6% above the Trend Line and sits at 13.1% of its 52-week range. The latest completed week returned -1.0%, after a -2.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2712-week average 0.13

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.27Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

5 accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.4% over four weeks, 7.0% over 12 weeks, and -35.6% over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W-1.0%
4W-2.4%
12W7.0%
26W10.6%
52W-35.6%
Active trend streak5 weeks
Active weeks in one year8
Trend breadth15.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.90Latest activity-pressure read.
Pressure change22.1%Four-week change in activity pressure.
Leadership-24.45Latest relative-leadership reading.
RS change17.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value51/100Relative valuation strength. Underlying universe rank 50; rank 1 is best.
Quality50/100Profitability and accounting quality. Underlying universe rank 51; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth52/100Revenue and earnings growth. Underlying universe rank 49; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
43.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-8.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-80.8%
Gross profit retained from each unit of revenue.
Operating margin
-529.7%
Operating profit retained from revenue.
Free-cash-flow margin
-354.4%
Free cash flow generated from revenue.
Return on invested capital
-9.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

JANX shows bullish options pressure with a 38/100 conviction score, put-call volume ratio of 0.46, expected move of 15.2%, and Sharemaestro trend signal active.

Conviction38/100
Expected move15.2%
Put/call volume0.46
Pressure38
Speculation0
Volatility79
Trend agreement54
Open options detail
Insider activity15 / 3

15 acquisitions and 3 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 57 relevant articles.

13 positive · 32 neutral · 12 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move15.2%Nearest-chain priced movement where available.
52-week drawdown-57.1%Distance below the 52-week high.
13-week volatility4.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+12.6%Week of 3 Apr.
Worst week-8.4%Week of 5 Jun.
Latest week-1.0%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains6
Flat weeks0
Modest losses6
Sharp losses6
Recent vol4.2%13-week weekly-return volatility.
Base vol9.5%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew5.6% / -6.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape29/100

Trend, activity pressure, participation, and risk combine to a 29/100 tape read.

 Indicator analysis51/100

Latest 12-week confirmation: trend 5/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.27; No reversal markers Next-Week ExpectancyNegative 43.46%

Next-week expectancy is negative with a 43.46% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 49; Small Cap Core rank 53 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options56/100

JANX shows bullish options pressure with a 38/100 conviction score, put-call volume ratio of 0.46, expected move of 15.2%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 15.2% Sentiment51/100

Weighted news tone is neutral across 57 relevant articles.

Form 4 Janux Therapeutics Inc For: 31 July By Investing.com Insiders15 / 3

15 acquisitions and 3 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202615.17 USD-1.0%14.36 USD27.31 USD0.90-24.453.9MOn
24 Jul 202615.33 USD-5.7%14.31 USD27.30 USD1.03-24.263.9MOn
17 Jul 202616.26 USD-0.9%14.28 USD27.28 USD1.18-22.153.9MOn
10 Jul 202616.40 USD5.5%14.19 USD27.26 USD1.04-25.875.1MOn
3 Jul 202615.54 USD4.0%14.16 USD27.24 USD0.74-29.515.1MOn
26 Jun 202614.94 USD5.1%14.19 USD27.21 USD0.40-32.5813.8MOff
19 Jun 202614.22 USD4.9%14.83 USD27.19 USD0.25-39.504.4MOff
12 Jun 202613.56 USD1.5%15.31 USD27.18 USD0.33-41.683.9MOff
5 Jun 202613.36 USD-8.4%15.84 USD27.18 USD0.42-42.203.2MOff
29 May 202614.59 USD0.5%16.28 USD27.17 USD0.54-40.794.1MOff
22 May 202614.52 USD4.5%16.75 USD27.17 USD0.48-40.276.6MOff
15 May 202613.89 USD-2.0%17.09 USD27.15 USD0.44-43.124.0MOff
8 May 202614.18 USD-1.2%17.52 USD27.14 USD0.49-43.004.4MOff
1 May 202614.34 USD-4.5%17.93 USD27.13 USD0.52-40.244.6MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.